CEL-SCI Corporation (CEL-SCI) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 1999.
Business Overview: CEL-SCI is a biotechnology company focused on the research and development of drugs and vaccines. The company has no commercial products currently on the market and generates no revenue from product sales. Its primary activities involve clinical trials for:
- MULTIKINE: A cytokine "cocktail" (IL-2 and other cytokines) being tested as a presurgical treatment for head and neck cancer and for improving immune response in HIV/AIDS patients.
- HGP-30W: An AIDS vaccine currently in Phase II clinical trials in the Netherlands.
- LEAPS Technology: A T-cell modulation system intended to direct specific immune responses for diseases including tuberculosis, malaria, and herpes simplex.
The company relies entirely on proceeds from the sale of securities (common and preferred stock) and borrowings to fund operations.
Key Financial Metrics
| Metric | Fiscal 1999 | Fiscal 1998 | Fiscal 1997 |
|---|---|---|---|
| Total Revenues | $469,518 | $792,994 | $438,145 |
| Net Loss | $(7,490,725) | $(6,442,683) | $(8,189,458) |
| Loss Per Share (Basic/Diluted) | $(0.52) | $(0.74) | $(1.00) |
| Research & Development Expenses | $4,461,051 | $3,833,854 | $6,011,670 |
| General & Administrative Expenses | $3,230,982 | $3,106,492 | $2,302,386 |
| Cash and Cash Equivalents | $2,746,531 | $2,813,225 | N/A |
| Investment Securities | $3,192,604 | $9,675,311 | N/A |
| Total Assets | $7,559,772 | $14,431,813 | $6,334,397 |
| Total Liabilities | $461,586 | $456,529 | $508,617 |
| Working Capital | $6,152,715 | $12,926,014 | $4,581,247 |
Note: Revenues consist entirely of investment income and other non-operating income. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Total income decreased by approximately 41% from $792,994 in 1998 to $469,518 in 1999. This was primarily due to a decrease in interest income as the company utilized proceeds from the sale of Series D Preferred Stock.
- Increased Operating Expenses: Research and Development (R&D) expenses increased by 16% ($627,197) compared to 1998, driven by the initiation of larger and more numerous clinical trials. General and Administrative (G&A) expenses increased by 4% due to additional staffing.
- Asset Reduction: Total assets decreased by $6.87 million (48%) from 1998 to 1999. This significant drop was largely due to the liquidation of investment securities (down from $9.68M to $3.19M) to fund operations.
- Stock Conversions: All 9,002 shares of Series D Preferred Stock were converted into approximately 4.76 million shares of common stock during the fiscal year.
Guidance, Outlook, and Risks
Outlook and Guidance: Management expects to spend between $3.5 million and $4.5 million on research, development, and clinical trials during fiscal 2000. The company is preparing to begin a Phase III study for MULTIKINE in the treatment of head and neck cancer. The company plans to use existing financial resources to fund these activities but explicitly states that substantial additional funds will be required for extensive clinical trials necessary for FDA approval.
Management Commentary: The company emphasizes that it has not realized revenues from operations since its inception in 1983. It remains dependent on the sale of securities to meet liquidity requirements. Management notes that commercial use of MULTIKINE may be several years away due to the extensive safety and efficacy testing required.
Risks and Contingencies:
- Liquidity Risk: The company has no assurance that additional financing will be available on favorable terms or at all. Without new capital, operations may cease.
- Regulatory Risk: There is no assurance that the FDA or other regulatory bodies will approve the company's products. Clinical trials conducted outside the U.S. (e.g., in Israel, Canada, Hungary) may not be accepted by the FDA.
- Legal Proceedings: In November 1999, two former directors filed a lawsuit alleging the April 1999 proxy statement was false and misleading regarding executive compensation and transactions. The company intends to deny these allegations.
- Competition: Intense competition exists from large pharmaceutical companies with significantly greater resources.
Investor Verification Checklist
- Cash Burn Rate: Verify the company's ability to sustain operations through fiscal 2000 given the $6.3 million net cash used in operating activities in 1999 and the projected $3.5M-$4.5M spend for 2000.
- Capital Raising Capability: Assess the likelihood of raising additional funds given the dilution from recent stock sales and the current market price of the common stock (traded between $1.88 and $3.81 in Q3 1999).
- Clinical Trial Progress: Monitor the results of the Phase III MULTIKINE study and the Phase II HGP-30W AIDS vaccine study, as these are critical for future valuation.
- Legal Status: Track the outcome of the shareholder lawsuit filed by former directors regarding executive compensation and fiduciary duties.
- Regulatory Pathway: Confirm the company's strategy for obtaining FDA approval, specifically regarding the acceptance of foreign clinical trial data.